Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) --

---

• Continued expansion of IP portfolio related to RNA delivery  
• Treatment of rheumatoid arthritis as one of the key therapeutic indications

HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.

The provisional patent application describes novel nanoparticle compositions based on OligoPhore, Altamira’s peptide-based oligonucleotide delivery platform, or derivatives thereof in combination with siRNA sequences designed to silence p65. Activation of p65 has been observed in multiple types of cancer as well as in many inflammatory diseases and its function has been implicated in the pathogenesis of these diseases. For instance, p65 is a well-known key checkpoint in rheumatoid arthritis (RA) inflammation, and thought to regulate cell proliferation, cell death, and stimulate metastasis in cancer. The new filing is intended to extend Altamira’s intellectual property related to its AM-411 development program for RA treatment, among others.

“We consider the treatment of arthritis one of the most promising applications of our OligoPhore RNA delivery platform,” commented Covadonga Pañeda, Ph.D., Altamira Therapeutics’ Chief Development Officer. “With our AM-411 program, we have demonstrated in vivo that we can deliver siRNA specifically to inflamed tissues, which in the case of RA is primarily the inflamed joints. The treatment is thus sparing non-inflamed tissues and avoiding the systemic side effects frequently observed with current treatment options. In addition, using siRNA to knock down the p65 protein allows to control a key inflammatory checkpoint, and promises not only potent treatment effects, but also a much-reduced risk of developing treatment resistance, another frequent issue with current treatment options.”